key: cord-0957186-eapu0a4q
authors: LaClair, Heather J.; Khosrodad, Nadia; Sule, Anupam A.; Koehler, Tracy; Krishnamoorthy, Geetha
title: Effect of ACE inhibitors and angiotensin receptor blockers on in-hospital mortality and length of stay in hospitalized COVID-19 patients
date: 2021-08-05
journal: Vascul Pharmacol
DOI: 10.1016/j.vph.2021.106902
sha: 3c388bd9a3c301134a7165f105427143ede4a8e4
doc_id: 957186
cord_uid: eapu0a4q

nan

and comorbidities [3] . We investigated if ACEi/ARB was associated with worse outcomes in hospitalized COVID-19 patients.

To achieve our objective, we performed a retrospective cohort study of 995 COVID-19 patients admitted between March 13th, 2020 and May 15th, 2020. Exposed patients were on ACEi/ARB previously at home which were continued in the hospital while control patients had no exposure to ACEi/ARB at home or in the hospital.

We performed multiple imputation for missing data using the MICE method and Rubin's rules were applied. Analyses included the t-test or Mann-Whitney test for quantitative data and Chisquare or Fisher's Exact test for categorical data. An adjusted cox regression model controlled for age, body mass index (BMI), race, sex, smoking status, congestive heart failure (CHF), hypertension (HTN), chronic obstructive pulmonary disease (COPD), asthma, diabetes, coronary artery disease (CAD), cerebrovascular accident/transient ischemic attack (CVA/TIA), glomerular filtration rate (GFR), neutrophil, lymphocyte, and inflammatory markers such as ferritin, ddimer, and C-reactive protein (CRP). Quantitative variables are reported as mean+SD or median

[IQR] for non-normally distributed data; nominal variables are reported as percentages.

Significance was assessed at p<0.05. All analyses were performed using STATA 13.1.

Of the 995 patients in the study, 241 were exposed to ACEi/ARB and 754 were not. ACEi/ARB patients were older, had higher percentage of former smoking, and patients with HTN, DM, CAD and CVA/TIA (Table 1) . There was no association between use of ACEi/ARB and in-hospital mortality; this finding held when analyzing intubated patients only (Table 2 ).

Journal Pre-proof Median length of stay (LOS) for non-intubated survivors was statistically similar between the groups. Rates of intubation were also similar.

We found no association between ACEi/ARB use and in-hospital mortality in hospitalized COVID 19 patients for both unadjusted and adjusted analyses. LOS and intubation rates were also similar between the groups. Inflammatory markers at admission between the exposed group and non-exposed group were similar, implying that both groups had the same amount of inflammatory reaction to COVID-19 and ACEi/ARB did not have a role in this inflammatory J o u r n a l P r e -p r o o f Journal Pre-proof pathway. Inflammatory markers, along with race and BMI, were controlled for in our analyses.

Our study adds to the growing evidence that discontinuation of ACEi/ARB is not clinically indicated in COVID-19 patients after diagnosis or hospitalization and should not be restricted in the community or hospital due to the COVID-19 pandemic. The benefits of appropriate ACEi/ARB use when indicated for cardiovascular indications outweigh any potential harm in COVID-19 patients.

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science (80-)

Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use with COVID-19 Diagnosis and Mortality

The authors declare they have no conflicts of interest.